Business
Med BioGene Inc. appoints Bruce Cousins as a director
Med BioGene Inc. appoints Bruce Cousins as a director.
About this update from Many Bright Ideas Technologies Inc
[{"type":"text","content":"\n\n\n\n\nVANCOUVER, June 5 /CNW/ - Med BioGene Inc. (\"MBI\") (TSX Venture: MBI) is\npleased to announce the appointment of Bruce Cousins, C.A., as a director of\nMBI.\nMr. Cousins is the Chief Financial Officer of Aspreva Pharmaceuticals\nCorporation (NASDAQ: ASPV; TSX: ASV) (www.aspreva.com). With Mr. Cousins as\nits CFO, Aspreva completed a $76 million private equity financing and a\n$113 million cross-border initial public offering on the Nasdaq National\nMarket and Toronto Stock Exchange - the largest initial public offering for a\nbiotechnology / biopharmaceutical company in Canadian history. Furthermore,\nduring his tenure, Mr. Cousins has seen Aspreva evolve into an emerging global\nbiopharmaceutical company with expected 2006 revenues to exceed\nUS$200 million.\nPrior to joining Aspreva, Mr. Cousins spent 14 years with Johnson &\nJohnson (J&J) as the World Wide Financial Director for J&J's Wound Management\nDivision in Somerville, New Jersey. As CFO of this US$500 million business\nunit, Mr. Cousins also held a key leadership role on the Global Management\nBoard. Prior to entering the pharmaceutical industry, Mr. Cousins was a\nchartered accountant with Deloitte & Touche.\n\"Bruce's experience and accomplishments in the industry will be\ninvaluable in assisting Med BioGene's efforts to develop its molecular\ndiagnostic tests,\" stated Erinn Broshko, Chief Executive Officer of MBI.\n\"Bruce greatly adds to our already strong board of directors and his\nappointment reflects positively on Med BioGene's future prospects.\"\n\"I am delighted to join Med BioGene at such an exciting time in the\ncompany's growth,\" stated Mr. Cousins. \"With a highly qualified scientific and\nsenior management team in place and a solid intellectual property portfolio,\nMed BioGene is well-positioned to be a leader in molecular diagnostics. I look\nforward to working with the other board members and senior management to make\nMed BioGene a success.\"\n\nCorporate Matters\n\nMBI has granted five-year incentive stock options to purchase an\naggregate of 150,000 common shares at an exercise price of $0.40 per share.\n\nAbout Med BioGene\n\nMBI is a biotechnology company with advanced research expertise in gene\nexpression technology. MBI's mission is to become a market leader in the\nsupply of content for molecular-based diagnostic mi...